JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

115.41

+1%↑

VEEV

160.84

+3.11%↑

Home・Akcijų sąrašas・BioNTech SE ADR

BioNTech SE ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

104.97 -0.49

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

104.72

Max

105.58

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-269M -302M
Pardavimai	-620M 899M
Pelno marža	-33.613
Darbuotojai	7,807
EBITDA	-217M -67M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+30.04% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	966M 27B
Ankstesnė atidarymo kaina	105.46
Ankstesnė uždarymo kaina	104.97

Naujienos nuotaikos

By Acuity

50%

186 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Very Strong Bearish Evidence

92.4 / 103.5 Palaikymas ir pasipriešinimas

BioNTech SE ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-06-02 11:48; UTC

Pagrindinės rinkos jėgos

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

2026-03-10 12:50; UTC

Uždarbis

BioNTech Stock Plunges 17% After Earnings. Why the Drugmaker Faces a Perfect Storm. -- Barrons.com

2026-03-10 11:18; UTC

Uždarbis

BioNTech Plunges as Drugmaker Swings to a Loss. More Than Earnings Are Weighing on the Stock. -- Barrons.com

2025-08-04 14:14; UTC

Uždarbis

BioNTech Stock Rises as Earnings Beat Expectations. Covid-19 Vaccine Sales Helped. -- Barrons.com

2025-08-04 11:59; UTC

Uždarbis

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

2025-06-12 14:20; UTC

Įsigijimai, susijungimai, perėmimai

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

2025-06-12 13:34; UTC

Karštos akcijos

Stocks to Watch Thursday: Boeing, Oracle, GameStop, CureVac -- WSJ

2025-06-10 12:18; UTC

Uždarbis

Why Moderna, Pfizer Stocks Are Shrugging Off RFK Jr.'s Firing of Vaccine Advisors. -- Barrons.com

2025-05-20 14:46; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Is Jumping Into a Hot Cancer-Drug Race. It May Have Overpaid. -- Barrons.com

2025-05-05 15:13; UTC

Rinkos pokalbiai

Uždarbis

Narrower Guidelines for Covid-19 Booster Wouldn't Limit BioNTech's Customer Base Much -- Market Talk

Akcijų palyginimas

Kainos pokytis

BioNTech SE ADR Prognozė

Kainos tikslas

By TipRanks

30.04% į viršų

12 mėnesių prognozė

Vidutinis 137.27 USD 30.04%

Aukščiausias 171 USD

Žemiausias 94 USD

Remiantis 16 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines BioNTech SE ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

16 ratings

Pirkti

Laikyti

Parduoti

Remiantis 16 analitikų, pateikusių BioNTech SE ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

92.4 / 103.5Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Rinkos nuotaikos

By Acuity

186 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę BioNTech SE ADR

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vac